Daniel Shames - 01 Jan 2024 Form 3 Insider Report for Mereo Biopharma Group plc (MREO)

Role
Director
Signature
/s/ Christine Fox, by power of attorney
Issuer symbol
MREO
Transactions as of
01 Jan 2024
Net transactions value
$0
Form type
3
Filing time
02 Jan 2024, 16:17:22 UTC
Next filing
09 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MREO Share Options (Right to buy) 01 Jan 2024 American Depositary Shares 9,167 $0.7900 Direct F1, F2
holding MREO Share Options (Right to buy) 01 Jan 2024 American Depositary Shares 55,000 $0.9400 Direct F1, F3
holding MREO Deferred Restricted Stock Units 01 Jan 2024 American Depositary Shares 64,777 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2 This award is fully vested and exercisable.
F3 Vests in substantially equal monthly installments over a one year period from the February 1, 2023 grant date.
F4 Each deferred restricted stock unit ("DRSU") was granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.

Remarks:

Exhibit 24 - Power of Attorney